Amphastar Pharmaceuticals:依据修正协议,公司将使用汉欣研发的研究细胞库为AMP-105制备主细胞库

美股速递
Mar 07

根据一项修正协议,Amphastar Pharmaceuticals将采用由汉欣公司开发的研究细胞库,专门用于为在研药物AMP-105制备主细胞库。这一安排旨在推进该候选药物的生产工艺开发。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10